Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir

Young, Jim; Schäfer, Juliane; Fux, Christoph A; Furrer, Hansjakob; Bernasconi, Enos; Vernazza, Pietro; Calmy, Alexandra; Cavassini, Matthias; Weber, Rainer; Battegay, Manuel; Bucher, Heiner C

doi:10.1097/QAD.0b013e32834f337c

Scientific article

English

Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir

ContributorsYoung, Jim; Schäfer, Juliane; Fux, Christoph A; Furrer, Hansjakob; Bernasconi, Enos; Vernazza, Pietro; Calmy, Alexandra

; Cavassini, Matthias; Weber, Rainer; Battegay, Manuel; Bucher, Heiner C

Published inAIDS, vol. 26, no. 5, p. 567-575

Publication date2012

Abstract

Tenofovir is associated with reduced renal function, but it is not clear whether there is a greater decline in renal function when tenofovir is co-administered with a boosted protease inhibitor rather than with a nonnucleoside reverse transcriptase inhibitor (NNRTI).

Keywords

Adenine/adverse effects/analogs & derivatives
Adult
Benzoxazines/adverse effects
Drug Therapy, Combination/adverse effects/methods
Female
Glomerular Filtration Rate/drug effects
HIV Infections/drug therapy
HIV Protease Inhibitors/administration & dosage/adverse effects
Humans
Kidney/drug effects/physiopathology
Lopinavir/adverse effects
Male
Middle Aged
Oligopeptides/adverse effects
Organophosphonates/adverse effects
Pyridines/adverse effects
Reverse Transcriptase Inhibitors/administration & dosage/adverse effects
Ritonavir/adverse effects
Treatment Outcome

Affiliation

Faculté de médecine / Section de médecine clinique / Département de médecine

Research group

VIH/SIDA (930)

Citation (ISO format)

YOUNG, Jim et al. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. In: AIDS, 2012, vol. 26, n° 5, p. 567–575. doi: 10.1097/QAD.0b013e32834f337c

Article (Published version)

Identifiers

PID : unige:31635
DOI : 10.1097/QAD.0b013e32834f337c
PMID : 22398568

ISSN of the journal0269-9370

502views

0downloads

Creation12/03/2013 2:47:00 PM

First validation12/03/2013 2:47:00 PM

Update time03/14/2023 8:40:03 PM

Status update03/14/2023 8:40:03 PM

Last indexation08/29/2023 7:25:01 AM

Archive ouverte UNIGE

Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir

Tenofovir is associated with reduced renal function, but it is not clear whether there is a greater decline in renal function when tenofovir is co-administered with a boosted protease inhibitor rather than with a nonnucleoside reverse transcriptase inhibitor (NNRTI).

Technical informations